Technical difficulties
NASDAQ delisting, raising finance with share price so low, they could easily take the slow road and self finance. If they have revenue they have Silicon Bank.
I don't see bad management, I see an approved product with old tech and poor targeting. Maybe too hard for anyone but SSH does know the HF landscape, including neurohormonal which is positive for Class3 Aquadex patients (not class 4) and does have considerable tech know how plus a new regulatory executive hire after the Aquadex purchase (from memory).
SHC Price at posting:
2.5¢ Sentiment: Buy Disclosure: Held
